Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 2, 2012, Pages 142-149

  Peters, Philip J ^a   Polle, Nicholas ^b,c   Zeh, Clement ^a   Masaba, Rose ^a   Borkowf, Craig B ^a   Oyaro, Boaz ^c   Omolo, Paul ^c   Ogindo, Paul ^c   Ndivo, Richard ^c   Angira, Frank ^c   Lando, Richard ^c   Fowler, Mary Glenn ^d   Weidle, Paul J ^a   Thomas, Timothy K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MINISTRY OF HEALTH   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

antiretroviral therapy; drug hypersensitivity; drug induced hepatitis; HIV; nevirapine; pregnancy; skin rash

Indexed keywords

COTRIMOXAZOLE; FLUCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LIVER TOXICITY; PHASE 3 CLINICAL TRIAL; PREGNANT WOMAN; PRIORITY JOURNAL; SIDE EFFECT; URTICARIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; KENYA; NELFINAVIR; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; YOUNG ADULT;

EID: 84859353720     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711423445     Document Type: Article

References (36)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. http://www.who.int/hiv. Published 2009. Accessed November 5, 2009.
2. Kenya AIDS Indicator Survey 2007 (KAIS 2007). Final report. http://www.aidskenya.org or http://www.nacc.or.ke/index.php? option=com-booklibrary&task=view&id=9&catid=124&Item id=122. Published 2009. Accessed May 5, 2011.
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795-802. (Pubitemid 29415583)
4. Leroy V, Ekouevi DK, Becquet R, et al. 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. PLoS One. 2008;3(2):e1645.
5. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding - the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8(3):e1001015.
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. http://whqlibdoc.who.int/publications/ 2010/9789241599764-eng.pdf. Published 2010. Accessed May 3, 2011.
7. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach. 2010 revision. http://www. who.int/hiv/pub/mtct/ antiretroviral2010/en/index.html. Published 2010. Accessed May 24, 2011.
8. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35(5): 538-539.
9. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36(3):772-776. (Pubitemid 38859341)
10. FDA advisory on nevirapine. AIDS Treat News. 2005;7. Published January 28, 2005
11. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007;44(4):371-376. (Pubitemid 46555370)
12. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194(1):199-202. (Pubitemid 43017797)
13. Kondo W, Carraro EA, Prandel E, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Braz J Infect Dis. 2007;11(6):544-548. (Pubitemid 351425834)
14. Ministry of Health, Government of Kenya. Guidelines for antiretroviral drug therapy in Kenya, 3rd ed; 2005. http://www.usaid. gov/ke/ke.buproc/AIDS- Indicator-Survey-KEN-2007.pdf. Accessed August 13, 2010.
15. World Health Organization. Antiretroviral therapy for HIV infection in adult and adolescents in resource-limited settings: towards universal access. http://www.who.int/hiv/pub/arv/en/index.html. Published 2006. Accessed June 10, 2009.
16. National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://www. niaid.nih.gov/ labsandresources/resources/daidsclinrsrch/documents/ daidsaegradingtable.pdf. Published Decemeber 2004. Accessed June 10, 2009.
17. Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC; 1991.
18. Peters PJ, Stringer J, McConnell MS, et al. Nevirapine-associated hepatotoxicity was not predicted by CD4 count >250 cells/μL among women in Zambia, Thailand and Kenya. HIV Med. 2010;11(10):650-660.
19. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reversetranscriptase inhibitors. Clin Infect Dis. 2004;38(suppl 2): S80-S89. (Pubitemid 38328169)
20. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7(4):255-260.
21. Natarajan U, Pym A, McDonald C, et al. Safety of nevirapine in pregnancy. HIV Med. 2007;8(1):64-69. (Pubitemid 46117843)
22. van Schalkwyk JE, Alimenti A, Khoo D, et al. Serious toxicity associated with continuous nevirapine-based HAART in pregnancy. BJOG. 2008;115(10):1297- 1302.
23. Imperiale M, Lanes S, Stern JO, Love J, Robinson P, Mayers D. The viramune (Nevirapine) hepatic safety project: analysis of symptomatic hepatic events. Antiviral Ther. 2002;7:L57.
24. Leith J, Piliero P, Storfer S, Mayers D, Hinzmann R. Appropriate use of nevirapine for long-term therapy. J Infect Dis. 2005;192(3): 545-546.
25. Otieno PA, Brown ER, Mbori-Ngacha DA, et al. HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis. 2007;195(2):220-229. (Pubitemid 46080054)
26. Ouyang DW, Shapiro DE, Lu M, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009;23(18): 2425-2430.
27. Peters PJ, Zulu I, Kancheya NG, et al. Modified Kigali combined staging predicts risk of mortality in HIV-infected adults in Lusaka, Zambia. AIDS Res Hum Retroviruses. 2008;24(7): 919-924.
28. Anthony LE. Effects of protein-calorie malnutrition on drug metabolism in rat liver microsomes. J Nutr. 1973;103(6): 811-820.
29. Bryson YJ, Mirochnick M, Stek A, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: pediatric AIDS clinical trials group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115-125. (Pubitemid 351804395)
30. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.
31. Strosnider H, Azziz-Baumgartner E, Banziger M, et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect. 2006; 114(12):1898-1903. (Pubitemid 44873692)
32. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185-1197. (Pubitemid 46763289)
33. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007;45(2):183-192. (Pubitemid 46869811)
34. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep. 2007;4(3):135-140. (Pubitemid 47493054)
35. Azziz-Baumgartner E, Gieseker K, Rogers HS, et al. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ Health Perspect. 2005;113(12):1779-1783. (Pubitemid 41794276)
36. Strosnider H, Azziz-Baumgartner E, Banziger M, et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect. 2006; 114(12):1898-1903 (Pubitemid 44873692)